--This application is a continuation-in-part of U.S. Application No. 09/403,672, having a filing date of March 27, 2000, now U.S. Patent No. 6,323,024, which is a national stage patent pursuant to 35 U.S.C. §371 of International Application No. PCT/US98/04291, which itself claims priority under 35 U.S.C. §120 to U.S. Application No. 08/812,742, now U.S. Patent No. 6,071,742, issued June 6, 2000. The entireties of each of the above-listed applications are incorporated by reference herein.—

D1

The paragraph beginning on page 15, line 30 was amended as set forth below.

D2

--Figure 12 shows a diagram of the multivalent CVB vaccine construct. The capsid protein 1D BC loops from CVB2 (B2) and CVB4 (B4) were inserted into the CVB3/0-derived subclone, pBSPL2.--

**In the claims:**

Please cancel claim 27 and enter amended claims 18 and 26 as set forth below.

D3

18. (Amended) The composition of claim 16, wherein the viral vector comprises a coxsackievirus B genome.

D4

26. (Amended) A method of suppressing onset of insulin-dependent diabetes mellitus in an individual, which comprises inoculating the individual as a juvenile or infant with a coxsackie B virus.